RT Journal Article
T1 Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry.
A1 Uribarri, Aitor
A1 Núñez-Gil, Iván J
A1 Aparisi, Alvaro
A1 Becerra-Muñoz, Victor M
A1 Feltes, Gisela
A1 Trabattoni, Daniela
A1 Fernández-Rozas, Inmaculada
A1 Viana-Llamas, María C
A1 Pepe, Martino
A1 Cerrato, Enrico
A1 Capel-Astrua, Thamar
A1 Romero, Rodolfo
A1 Castro-Mejía, Alex F
A1 El-Battrawy, Ibrahim
A1 López-País, Javier
A1 D'Ascenzo, Fabrizio
A1 Fabregat-Andres, Oscar
A1 Bardají, Alfredo
A1 Raposeiras-Roubin, Sergio
A1 Marín, Francisco
A1 Fernández-Ortiz, Antonio
A1 Macaya, Carlos
A1 Estrada, Vicente
A1 HOPE COVID-19 Investigators, 
K1 Acute kidney injury
K1 COVID-19
K1 Chronic kidney failure
K1 Mortality
K1 Prognosis
K1 Registry
AB Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite its international aggressive extension, with a significant morbidity and mortality, the impact of renal function on its prognosis is uncertain. Analysis from the international HOPE-Registry (NCT04334291). The objective was to evaluate the association between kidney failure severity on admission with the mortality of patients with SARS-CoV-2 infection. Patients were categorized in 3 groups according to the estimated glomerular filtration rate on admission (eGFR > 60 mL/min/1.73 m2, eGFR 30-60 mL/min/1.73 m2 and eGFR  60 mL/min/1.73 m2, eGFR 30-60 mL/min/1.73 m2 and eGFR  758 patients were included: mean age was 66 ± 18 years, and 58.6% of patient were male. Only 8.5% of patients had a history of chronic kidney disease (CKD); however, 30% of patients had kidney dysfunction upon admission (eGFR  60 vs eGFR 30-60 vs and eGFR  Renal failure on admission in patients with SARS-CoV-2 infection is frequent and is associated with a greater number of complications and in-hospital mortality. Our data comes from a multicenter registry and therefore does not allow to have a precise mortality risk assessment. More studies are needed to confirm these findings.
YR 2020
FD 2020-06-29
LK http://hdl.handle.net/10668/15851
UL http://hdl.handle.net/10668/15851
LA en
DS RISalud
RD Apr 7, 2025